Eosinophilic esophagitis (EoE) is a rapidly emerging medical condition (affecting one in 2,000 people globally) caused by eosinophil infiltration into the esophagus and GI tract. Current treatments do not address the underlying cause of EoE; namely, esophageal immune cell infiltration. A University of Colorado research team has found that a monoclonal antibody targeting granulocyte-macrophage colony-stimulating factor (GM-CSF) may be a potential treatment for EoE. In a mouse model, the inventors reduced GM-CSF levels by administering a GM-CSF neutralizing monoclonal antibody and found that it diminished some negative consequences of EoE, such as eosinophil infiltration into the esophagus, basal cell hyperplasia, and angiogenesis.
Download Summary Document Here:
http://cuamc.technologypublisher.com/files/sites/cu4149h_ncs.pdf